来曲唑用于多囊卵巢综合征患者促排卵的临床疗效及安全性评价

发布时间：2018-06-25 03:30

本文选题：多囊卵巢综合征 + 来曲唑　；参考：《中国临床药理学杂志》2015年19期

【摘要】：目的评价不同剂量来曲唑用于多囊卵巢综合征患者促排卵的临床疗效和安全性。方法将88例拟进行促排卵治疗的多囊卵巢综合征患者随机分为对照组42例和试验组46例。2组患者均于月经来潮第3天起开始服药,对照组予以口服来曲唑2.5 mg·d-1,连续5 d;试验组予以口服来曲唑5 mg·d-1,连续5 d。月经周期第10天,开始进行阴道超声检查,并监测卵泡发育情况,比较2组患者的排卵率和周期妊娠率以及不良反应发生率。结果对照组有33例排卵,排卵率78.57%,临床妊娠2例,周期妊娠率为6.1%(2/33),试验组有34例排卵,排卵率为73.91%,临床妊娠9例,周期妊娠率为26.5%(9/34),其中试验组周期妊娠率显著高于对照组(P0.05)。对照组与试验组成熟卵泡数分别为(1.0±0.4)个和(1.5±0.6)个,试验组显著高于对照组(P0.05)。对照组用药期间发生关节痛2例、恶心1例,试验组发生关节痛1例、恶心1例,2组患者不良反应发生率比较差异无统计学意义(P0.05)。结论 5.0 mg·d-1来曲唑与2.5 mg·d-1来曲唑相比可显著提高多囊卵巢综合征患者的周期妊娠率,同时不增加不良反应风险。
[Abstract]:Objective to evaluate the clinical efficacy and safety of different doses of letrozole for ovulation in patients with polycystic ovary syndrome (PCOS). Methods 88 patients with polycystic ovary syndrome (PCOS) were randomly divided into control group (42 cases) and experimental group (46 cases.2). The patients were treated with menstrual flow for third days, and the control group was given letrozole 2.5. Mg. D-1, 5 d consecutive; the test group took orally letrozole 5 mg D-1, 5 d. menstrual cycle for tenth days, and began to carry out the vaginal ultrasound examination, and monitor the follicular development, compare the ovulation rate and cycle pregnancy rate and the incidence of adverse reactions in the 2 groups of patients. The control group had 33 cases of ovulation, the rate of ovulation 78.57%, clinical pregnancy 2 cases, periodic pregnancy. The rate was 6.1% (2/33). In the experimental group, 34 cases were ovulation, the ovulation rate was 73.91%, the clinical pregnancy was 9, and the cycle pregnancy rate was 26.5% (9/34). The period pregnancy rate of the experimental group was significantly higher than that of the control group (P0.05). The control group and the test group were (1 + 0.4) and (1.5 + 0.6) respectively, and the test group was significantly higher than the control group (P0.05). There were 2 cases of joint pain and 1 cases of nausea. There were 1 cases of joint pain in the experimental group and 1 cases of nausea. There was no significant difference in the incidence of adverse reactions between the 2 groups (P0.05). Conclusion 5 mg. D-1, letrozole and 2.5 mg. D-1 can significantly increase the cycle pregnancy rate of the patients with polycystic ovary syndrome and do not increase the risk of adverse reactions.
【作者单位】：福建医科大学附属第一医院妇产科;
【基金】：福建省卫生厅青年基金资助项目(0013023)
【分类号】：R711.75

【相似文献】